Moxetumomab pasudotox and hairy cell leukemia: results of a pivotal studyMoxetumomab pasudotox and hairy cell leukemia: results of a pivotal study
Robert Kreitman, MD, from the National Cancer Institute, Bethesda, MD, discusses a clinical trial using the recombinant immunotoxin, moxetumomab pasudotox, in patients with relapsed/refractory hairy c... Author: VJHemOnc Added: 06/29/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 29, 2018 Category: Cancer & Oncology Source Type: podcasts

Moxetumomab Pasudotox Pivotal in relapse refractory hairy cell leukemia
Michelle Dawson, MD, AstraZeneca, talks about Moxetumomab Pasudotox Pivotal in relapse refractory hairy cell leukemia at ASCO 2018. Author: Annual-Meeting Added: 06/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 6, 2018 Category: Cancer & Oncology Source Type: podcasts

Hairy cell leukemia: New targets, new therapy
This outstanding webcast of Lymphoma & Myeloma 2013, an International Congress on Hematologic Malignancies, includes experts presenting the current issues and clinical trial information in lymphom... Author: imedex Added: 12/22/2013 (Source: Oncology Tube)
Source: Oncology Tube - December 22, 2013 Category: Cancer & Oncology Source Type: podcasts